Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 3/2014

01.06.2014 | Research Article

Inappropriate prescribing in patients accessing specialist palliative day care services

verfasst von: A. Todd, H. Nazar, S. Pearson, I. Andrew, L. Baker, A. Husband

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Background For patients accessing specialist palliative care day services, medication is prescribed routinely to manage acute symptoms, treat long-term conditions or prevent adverse events associated with these conditions. As such, the pharmacotherapeutic burden for these patients is high and polypharmacy is common. Consequently, the risk of these patients developing drug-related toxicities through drug–drug interactions is exacerbated. Medication use in this group should, therefore, be evaluated regularly to align with achievable therapeutic outcomes considering remaining life expectancy. Objective To (1) assess the prevalence of inappropriate medication use; (2) identify potential drug–drug interactions; and, (3) determine how many potential drug–drug interactions could be prevented by discontinuing inappropriate medication. Setting A specialist tertiary care palliative care centre in Northern England serving a population of 330,000. Main outcome measure Prescribing of inappropriate medication. Method Medication histories for patients accessing a specialist palliative day care centre were established and a modified Delphi method was used to reach consensus of medication appropriateness. The Delphi method utilized a framework considering the following factors: remaining life expectancy of the patient, time until benefit of the treatment, goals of care and treatment targets. Potential drug interactions were established using drug interaction recognition software and categorised by their ability to cause harm. Results A total number of 132 patients were assessed during the study period who were prescribed 1,532 (mean = 12/patient) medications; 238 (16 %) were considered inappropriate in the context of limited life expectancy. The most common class of medications considered inappropriate were the statins, observed in 35 (27 %) patients. A total of 267 potential drug–drug interactions were identified; 112 were clinically significant and 155 were not considered clinically significant. Discontinuation of inappropriate medication would reduce the total number of medications taken to 1,294 (mean = 10/patient) and prevent 31 clinically significant potential drug–drug interactions. Conclusion Patients accessing specialist palliative day care services take many inappropriate medications. These medications not only increase the pharmacotherapeutic burden for the patient but they also contribute to potential drug–drug interactions. These patients should have their medication reviewed in the context of life limiting illness aligned with achievable therapeutic outcomes.
Literatur
1.
Zurück zum Zitat Potter J, Hami F, Bryan T, Quigley C. Symptoms in 400 patients referred to palliative care services: prevalence and patterns. Palliat Med. 2003;17:310–4.PubMedCrossRef Potter J, Hami F, Bryan T, Quigley C. Symptoms in 400 patients referred to palliative care services: prevalence and patterns. Palliat Med. 2003;17:310–4.PubMedCrossRef
2.
Zurück zum Zitat Sera L, McPherson ML, Holmes HM. Commonly prescribed medications in a population of hospice patients. Am J Hosp Palliat Care. 2013; Feb 12 (Epub ahead of print). Sera L, McPherson ML, Holmes HM. Commonly prescribed medications in a population of hospice patients. Am J Hosp Palliat Care. 2013; Feb 12 (Epub ahead of print).
3.
Zurück zum Zitat Koh NY, Koo WH. Polypharmacy in palliative care: can it be reduced? Singap Med J. 2002;43(6):279–83. Koh NY, Koo WH. Polypharmacy in palliative care: can it be reduced? Singap Med J. 2002;43(6):279–83.
4.
Zurück zum Zitat Rottlaender D, Scherner M, Schneider T, Erdmann E. Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany. Dtsch Med Wochenschr. 2007;132(4):139–44.PubMedCrossRef Rottlaender D, Scherner M, Schneider T, Erdmann E. Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany. Dtsch Med Wochenschr. 2007;132(4):139–44.PubMedCrossRef
5.
Zurück zum Zitat Riechelmann RP, Zimmermann C, Chin SN, Wang L, O’Carroll A, Zarinehbaf S, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manag. 2008;35:535–43.CrossRef Riechelmann RP, Zimmermann C, Chin SN, Wang L, O’Carroll A, Zarinehbaf S, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manag. 2008;35:535–43.CrossRef
6.
Zurück zum Zitat Girre V, Arkoub H, Puts MT, Vantelon C, Blanchard F, Droz JP, et al. Potential drug interactions in elderly cancer patients. Crit Rev Oncol Hematol. 2011;78:220–6.PubMedCrossRef Girre V, Arkoub H, Puts MT, Vantelon C, Blanchard F, Droz JP, et al. Potential drug interactions in elderly cancer patients. Crit Rev Oncol Hematol. 2011;78:220–6.PubMedCrossRef
7.
Zurück zum Zitat Currow DC, Abernethy AP. Frameworks for approaching prescribing at the end of life. Arch Intern Med. 2006;166(21):2404.PubMed Currow DC, Abernethy AP. Frameworks for approaching prescribing at the end of life. Arch Intern Med. 2006;166(21):2404.PubMed
8.
Zurück zum Zitat Hall PS, Lord SR, El-Laboudi A, Seymour MT. Non-cancer medications for patients with incurable cancer: time to stop and think? Br J Gen Pract. 2010;60(573):243–4.PubMedCentralPubMedCrossRef Hall PS, Lord SR, El-Laboudi A, Seymour MT. Non-cancer medications for patients with incurable cancer: time to stop and think? Br J Gen Pract. 2010;60(573):243–4.PubMedCentralPubMedCrossRef
9.
10.
Zurück zum Zitat Nicholson A, Andrew I, Etherington R, Gamlin R, Lovel T, Lloyd J. Futile and inappropriate prescribing: an assessment of the issue in a series of patients admitted to a specialist palliative care unit. Int J Pharm Pract. 2001;9(S1):72.CrossRef Nicholson A, Andrew I, Etherington R, Gamlin R, Lovel T, Lloyd J. Futile and inappropriate prescribing: an assessment of the issue in a series of patients admitted to a specialist palliative care unit. Int J Pharm Pract. 2001;9(S1):72.CrossRef
12.
Zurück zum Zitat Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS ONE. 2011;6(6):e20476.PubMedCentralPubMedCrossRef Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS ONE. 2011;6(6):e20476.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166(6):605–9.PubMedCrossRef Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166(6):605–9.PubMedCrossRef
14.
Zurück zum Zitat Hsu CC, Sandford BA. The Delphi technique: making sense of consensus. Pract Assess Res Eval. 2007;12(10):1–8. Hsu CC, Sandford BA. The Delphi technique: making sense of consensus. Pract Assess Res Eval. 2007;12(10):1–8.
16.
Zurück zum Zitat Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99(8):592–600.PubMedCrossRef Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99(8):592–600.PubMedCrossRef
17.
Zurück zum Zitat Baxter K, Preston CL. Stockley’s drug interactions. 10th ed. UK: Pharmaceutical Press; 2013. ISBN 978 0 85711 061 9. Baxter K, Preston CL. Stockley’s drug interactions. 10th ed. UK: Pharmaceutical Press; 2013. ISBN 978 0 85711 061 9.
19.
Zurück zum Zitat Todd A, Williamson S, Husband A, Baqir W, Mahony M. Patients with advanced lung cancer: is there scope to discontinue inappropriate medication? Int J Clin Pharm. 2013;35:181–4.PubMedCrossRef Todd A, Williamson S, Husband A, Baqir W, Mahony M. Patients with advanced lung cancer: is there scope to discontinue inappropriate medication? Int J Clin Pharm. 2013;35:181–4.PubMedCrossRef
20.
Zurück zum Zitat Riechelmann RP, Krzyzanowska MK, Zimmermann C. Futile medication use in terminally ill cancer patients. Support Care Cancer. 2009;17(6):745–8.PubMedCrossRef Riechelmann RP, Krzyzanowska MK, Zimmermann C. Futile medication use in terminally ill cancer patients. Support Care Cancer. 2009;17(6):745–8.PubMedCrossRef
21.
Zurück zum Zitat Fede A, Miranda M, Antonangelo D, Trevizan L, Schaffhausser H, Hamermesz B, et al. Use of unnecessary medications by patients with advanced cancer: cross-sectional survey. Support Care Cancer. 2011;19:1313–8.PubMedCrossRef Fede A, Miranda M, Antonangelo D, Trevizan L, Schaffhausser H, Hamermesz B, et al. Use of unnecessary medications by patients with advanced cancer: cross-sectional survey. Support Care Cancer. 2011;19:1313–8.PubMedCrossRef
22.
Zurück zum Zitat van Leeuwen RW, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol. 2011;22(10):2334–41.PubMedCrossRef van Leeuwen RW, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol. 2011;22(10):2334–41.PubMedCrossRef
23.
Zurück zum Zitat Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H, Ohashi K. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res. 2005;28(3):223–7.PubMedCrossRef Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H, Ohashi K. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res. 2005;28(3):223–7.PubMedCrossRef
25.
Zurück zum Zitat Steiness E. Diuretics, digitalis and arrhythmias. Acta Med Scand Suppl. 1981;647:75–8.PubMed Steiness E. Diuretics, digitalis and arrhythmias. Acta Med Scand Suppl. 1981;647:75–8.PubMed
26.
Zurück zum Zitat British National Formulary 64, September 2012. UK: Pharmaceutical Press. ISBN 978-0857110657. British National Formulary 64, September 2012. UK: Pharmaceutical Press. ISBN 978-0857110657.
27.
Zurück zum Zitat Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Renal Insufficiency and Cancer Medications (IRMA) Study Group: prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376–84.PubMedCrossRef Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Renal Insufficiency and Cancer Medications (IRMA) Study Group: prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376–84.PubMedCrossRef
28.
29.
Zurück zum Zitat Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716–24.PubMedCrossRef Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716–24.PubMedCrossRef
30.
Zurück zum Zitat Hanlon JT, Schmader KE, Samsa GP. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45:1045–51.PubMedCrossRef Hanlon JT, Schmader KE, Samsa GP. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45:1045–51.PubMedCrossRef
31.
Zurück zum Zitat Gallagher P, Ryan C, Byrne S. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert Doctors To Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46:72–83.PubMedCrossRef Gallagher P, Ryan C, Byrne S. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert Doctors To Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46:72–83.PubMedCrossRef
32.
Zurück zum Zitat Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–9.
33.
Zurück zum Zitat Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk: pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623.PubMedCrossRef Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk: pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623.PubMedCrossRef
34.
Zurück zum Zitat Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.CrossRef Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.CrossRef
35.
Zurück zum Zitat Callahan AS. Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms. Curr Atheroscler Rep. 2003;5(1):33–7.PubMedCrossRef Callahan AS. Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms. Curr Atheroscler Rep. 2003;5(1):33–7.PubMedCrossRef
36.
Zurück zum Zitat Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162(19):2197–202.PubMedCrossRef Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162(19):2197–202.PubMedCrossRef
38.
Zurück zum Zitat Bayliss EA, Bronsert MR, Reifler LM, Ellis JL, Steiner JF, McQuillen DB, et al. Statin prescribing patterns in a cohort of cancer patients with poor prognosis. J Palliat Med. 2013;16(4):412–8.PubMedCentralPubMedCrossRef Bayliss EA, Bronsert MR, Reifler LM, Ellis JL, Steiner JF, McQuillen DB, et al. Statin prescribing patterns in a cohort of cancer patients with poor prognosis. J Palliat Med. 2013;16(4):412–8.PubMedCentralPubMedCrossRef
39.
Zurück zum Zitat Tanvetyanon T, Choudhury AM. Physician practice in the discontinuation of statins among patients with advanced lung cancer. J Palliat Care. 2006;22(4):281–5.PubMed Tanvetyanon T, Choudhury AM. Physician practice in the discontinuation of statins among patients with advanced lung cancer. J Palliat Care. 2006;22(4):281–5.PubMed
40.
Zurück zum Zitat Stavrou EP, Buckley N, Olivier J, Pearson SA. Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage. BMJ Open. 2012;2:e000880.PubMedCentralPubMedCrossRef Stavrou EP, Buckley N, Olivier J, Pearson SA. Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage. BMJ Open. 2012;2:e000880.PubMedCentralPubMedCrossRef
41.
Zurück zum Zitat Schuling J, Gebben H, Veehof LJ, Haaijer-Ruskamp FM. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract. 2012;13:56.PubMedCentralPubMedCrossRef Schuling J, Gebben H, Veehof LJ, Haaijer-Ruskamp FM. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract. 2012;13:56.PubMedCentralPubMedCrossRef
Metadaten
Titel
Inappropriate prescribing in patients accessing specialist palliative day care services
verfasst von
A. Todd
H. Nazar
S. Pearson
I. Andrew
L. Baker
A. Husband
Publikationsdatum
01.06.2014
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 3/2014
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-014-9932-y

Weitere Artikel der Ausgabe 3/2014

International Journal of Clinical Pharmacy 3/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.